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Background: Asbestos-related malignant pleural mesothelioma 
is one of the most lethal tumor types. The advent of antimetabolite 
treatment as pemetrexed, introduced in the early 2000s, may have 
increased survival on a population basis. In this study, we have ana-
lyzed population-based incidence and survival data over the last 
40 years.
Methods:Complete national data on 1686 patients from the 
Cancer Registry of Norway sampled from 1970 to 2009 are pre-
sented, with incidence rates in 5-year periods. Relative survival for 
1 year and 3 years and median survival in 5-year intervals were 
calculated.
Results: The incidence of malignant pleural mesothelioma has been 
significantly and steadily increasing from 1970 until 2009, with 50 
patients diagnosed in the period 1970–1974 and 377 diagnosed in 
2005–2009. The incidence was highest among men in all time peri-
ods. A slight decline was observed in the last period. The 1-year 
survival rate increased from 20.7% to 44.0% during the period 1970–
2009, whereas the 3-year survival rate remained below 10%. Median 
survival increased from 4.0 months in the first period to 9.3 months 
in the last period.
Conclusions:  The incidence of malignant pleural mesothelioma 
follows the curve of asbestos exposure with a 20- to 40-year lag. 
There has been a significant increase in survival, most likely 
because of earlier diagnosis and improvements in cytostatic 
treatment.
Key Words: Mesothelioma, Survival, Prognostic factors, Population-
based study, Pemetrexed.
(J Thorac Oncol. 2012;7: 1858–1861)
Malignant pleural mesothelioma causally linked to asbes-tos exposure is a relatively rare cancer, still estimated to 
affect 25,000 to 43,000 persons yearly worldwide.1–4 Although 
the overwhelming majority of pleural mesotheliomas are 
attributable to asbestos, a few other causes have been identi-
fied. There are indications that multiwalled nanotubes might 
be a potential mesothelioma risk factor.5 Mesothelioma is also 
a well-known complication of therapeutic radiation for lym-
phoma, breast cancer, lung cancer, and other malignancies.6
The latency period is thought to be as long as 40 years 
or more between asbestos exposure and the development of 
mesothelioma.7 The incidence of malignant pleural mesothe-
lioma is significantly higher in men, possibly because of occu-
pational asbestos exposure. As the commercial use of asbestos 
has been banned for some decades in Europe, it has been pre-
dicted that the incidence of male mesotheliomas will decline 
after 2015–2020.8 Recent studies have shown that patients 
with malignant mesothelioma have a median overall survival 
of 7 to 10 months.9,10
The results of curatively intended treatment for pleural 
mesothelioma are largely disappointing. Surgery may be an 
option for a small subset of patients whereas radiotherapy has 
only palliative effects. Mesothelioma was earlier regarded as 
chemoresistant, but this modality is now incorporated in stan-
dard care.
In this study we have population-based data of 
mesothelioma incidence and survival from Norway, in the 
period from 1970 to 2009. During this period, the diagnostic 
possibilities were improved, especially because of increased 
use of computed tomography scanning from the mid 1970s. 
Not the least, after the phase III study by Vogelzang et al.11 
on pemetrexed in malignant pleural mesotheliomas, treatment 
with this antimetabolite was introduced in Norway in the 
early 2000s. We here report incidence and survival data on a 
national level, before and after introduction of this treatment.
PATIENTS AND METHODS
Population Demographics
Norway, with a population of 5 million, has a universal 
public health service financed by taxation and a national insur-
ance scheme accessible to all residents, independent of social 
or economic status. This includes funding of chemotherapy. In 
the period studied, the proportion of citizens of non-Western 
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origin fluctuated from 1.3% to 4.9%. In our data set no subset 
analysis was conducted based on race, socioeconomic status, 
or geography.
Data Collection
Since 1952 all malignant neoplasms have been reported 
to the Cancer Registry of Norway. In addition, copies of cytol-
ogy, biopsy, and autopsy reports are submitted from pathology 
laboratories and death certificate reports are submitted from 
the Cause of Death Register run by the National Statistics 
Bureau, Statistics Norway. Since 1998 all hospitals have filed 
discharge summaries electronically to the registry. The system 
of reporting to the Cancer Registry of Norway was evaluated 
in 2009, and overall completeness of reporting was estimated 
at 98.8%.12
Data on mesothelioma patients undergoing surgery were 
collected from the Norwegian register for general thoracic 
surgery13 and the Danish National Hospital, Copenhagen, 
Denmark.
Pemetrexed was introduced in Norway through a com-
passionate-use program initiated in 2003. Data on the usage 
of pemetrexed for mesothelioma patients the first 2 years was 
provided by Eli Lilly & Co. From 2005, pemetrexed was also 
given to lung cancer patients. From then on, no data are avail-
able on the selective use of pemetrexed in the mesothelioma 
population.
Patient Follow-Up
Mortality updates are conducted routinely by the Cancer 
Registry of Norway through linkage with the Cause of Death 
Register. In survival analyses, the primary outcome was 
survival after a diagnosis of mesothelioma. Follow-up was 
defined as the time from mesothelioma diagnosis to death as 
reported from the Cause of Death Register or to the last date 
of data submission for patients who were still alive, whichever 
came first.
Statistical Methods
We divided the study period into calendar years. 
Incidence data are presented as age-adjusted by the direct 
method to the standard world population. We calculated 1- 
and 5-year male and female relative survival for individuals 
diagnosed through successive 5-year calendar periods. We 
estimated relative survival for men and women using the 
method of Hakulinen, where the survival time of the matched 
individual is censored at the same survival time as that of the 
patient with cancer.14 Relative survival adjusts for competing 
causes of death expected for persons of the same sex, age, and 
calendar year of investigation (the ratio of observed survival 
in a population to the expected survival rate); hence, cause of 
death information is not required.
RESULTS
Incidence
The incidence has increased steadily from 1970 to 
2004, from 50 patients during 1970–1974 to 377 patients in 
the period 2005–2009 (Fig. 1A). The incidence is significantly 
higher in men than in women (p = 0.0016), with a male-to-
female ratio of 4.0 to 4.8:1 throughout the period. The increase 
in men has been 7.8-fold over the 40-year period, whereas the 
increase in females has been 6.5-fold. The rates per 1,00,000 
increased from 0.1 in 1970 in women to 0.3 in 2005–2009. In 
men the rates increased from 0.3 in 1970–1974 to a peak of 1.6 
in 2000–2004, slightly decreasing to 1.5 in 2005–2009. This 
corresponds to an average absolute annual increase of 5.4 % 
in men and 4.9% in women, whereas the age-adjusted annual 
increase has been 4.2% and 2.9%, respectively (Fig. 1B).‘
Treatment
Most patients with malignant pleural mesothelioma 
present with extensive disease, and receive palliative 
chemotherapy and/or radiotherapy. Less than 10% of these 
patients undergo surgery for treatment. During the last 
years, surgery for this disease has been centralized to the 
Department of Thoracic Surgery in Copenhagen, Denmark, 
where 25 Norwegian patients underwent surgery in the period 
2004–2011. In 15 patients, extrapleural pneumonectomies 
were performed and in 10 decortication was done. In Norway, 
five pneumonectomies and one decortication were performed 
in the period 2003–2010, according to the national registry for 
thoracic surgery. In addition, presumably, a very small number 
of patients might have on their own expense undergone 
surgical procedures outside of Norway or Denmark.
FIGURE 1.  Absolute (upper panel) and age-adjusted (lower 
panel) increase of mesothelioma incidence in Norway for 
men (blue line) and women (red line) from 1970 to 2009.
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Radiotherapy is often used as palliative treatment for 
this patient group in Norway, but doses delivered are very sel-
dom more than 50 Gy. Less than 50% of the patients receive 
this modality, and there has been no trend in increased use of 
radiation therapy (data not shown).
After introduction of pemetrexed in the treatment of 
mesothelioma in Norway in February 2003, patients with 
malignant pleural mesothelioma have been treated with this 
drug mainly in combination with cisplatin or carboplatin. 
The first 2 years, 65 mesothelioma patients were treated with 
pemetrexed, corresponding to approximately 40% of the diag-
nosed cases (Fig. 2).
Survival
The 1-year survival increased significantly during 1970–
2009 in both sexes, from 10% to 20% in the early 1970s, fluc-
tuating between 30% and 35% through the 1980s and 1990s 
and reaching 44.0% (p = 0.0014) and 41.3% (p = 0.029) in 
men and women, respectively in the last period (Fig. 3). The 
3-year survival has been below 10% throughout the period 
(nonsignificant change).
The median survival increased during the 1970s, seem-
ing to reach a plateau of approximately 7 months in the 1980s 
and 1990s. During the last decade, there has been an increase 
in median survival, being 9.3 months in men in the last period 
of study (Fig. 4). The increase throughout the study period 
was statistically significant in both sexes (p = 0.0016 in men, 
and p = 0.05 in women).
DISCUSSION
This study confirms the increase in incidence of malig-
nant pleural mesothelioma over the last 40 years, as observed 
elsewhere.9,15 The incidence in men has remained substan-
tially higher than in women, but the increase rate in women 
has been almost as high as in men. It has been estimated that 
the incidence of this diagnosis will increase with a predicted 
peak in 2015–2020 in Europe.8 Our data indicate that the inci-
dence-peak in men has been reached in Norway, with a slight 
decline in adjusted rate per 1,00,000 during the last 5-year 
period. This might be explained by the fact that restrictions 
on asbestos usage were implemented in 1974 in Norway, as 
one of the first nations. A general ban on import and use was 
established from 1984 and further restricted in 1991. In most 
other Western countries similar restrictions were implemented 
FIGURE 2.  The antimetabolite pemetrexed was not used in 
Norway before 2003; the first patient was treated in February 
2003, and during the first 2 years 65 patients received this 
treatment.
FIGURE 3.  Survival for 1 year and 3 years for women (upper 
panel) and men (lower panel) over the last 40 years. OS, 
overall survival.
FIGURE 4.  Median survival for men diagnosed with malig-
nant mesothelioma from 1970 to 2009. Ninety-five percent 
confidence intervals are shown.
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later, notably in Germany from 1993, France from 1996, and 
Great Britain from 1999.16
The 1-year survival has increased from approximately 
20% in the 1970s, to well over 40% in the later years. This 
may have been because of several causes. The diagnostics 
have improved since 1970, with computed tomography being 
available from the mid 1970s, and it is likely that in general, the 
disease has been diagnosed in earlier stages in the recent years. 
Few surgeons seem enthusiastic regarding extensive surgery 
for these patients. The effect of extrapleural pneumonectomy 
has been reported to be of no positive and possible harmful 
effect regarding survival in these patients.17 However, the facts 
that 12 hospitals were engaged, and only 16 of 24 patients 
randomized to surgery were operated with a somewhat high 
30-day mortality indicate that a firm conclusion regarding the 
place of surgery cannot be drawn. With the exception of a very 
small subset of patients, it is assumed that radical surgery in 
terms of an R0 resection cannot be achieved in patients with 
malignant pleural mesothelioma. Furthermore, radiotherapy 
is given in palliative doses only, and there does not seem to 
be a trend of increasing doses or increased frequency of 
this modality. Other studies have not shown any significant 
survival effect of radiotherapy for mesothelioma.18 Therefore, 
the advent of chemotherapy, especially the introduction of 
pemetrexed from 2003, most probably has contributed to the 
increased median and 1-year survival observed in the later 
years.19 Our data are consistent with this view, as we see an 
increase in median survival through the 1970s, reaching a 
plateau in the 1980s and 1990s. This is presumably because of 
earlier diagnosis caused by increased and improved computed 
tomography-based diagnostic, but no significant advance in 
treatment. However, over the last 10-year period, a significant 
improvement in median survival, from approximately 7 
months (6.8 months in 1995–1999), to more than 9 months (9.3 
months in 2004–2009) was observed, pointing to a substantial 
contribution from chemotherapy also on a population level. This 
is in concordance with recent results from The Netherlands, 
which also showed a coincidence of improved survival and 
introduction of pemetrexed for mesothelioma.20 Even though we 
have no data on pemetrexed usage in the mesothelioma group 
selectively after 2004, there are no indications that the patient 
group has been chemotherapy treated to a lesser extent than 
during the first years. Before the introduction of pemetrexed, 
a number of different chemotherapy regimens were tried for 
mesothelioma patients. These included metothrexate, cisplatin 
and trofosphamide, either in combination or as monotherapies. 
None of these were regarded as standard treatment, and were 
probably used in a minority of patients only.
The incidence of malignant pleural mesothelioma may be 
declining in several Western countries. Nevertheless, it will take 
several decades—if ever—before the disease has returned to an 
incidence rate so low that it could be neglected by the medical 
community. In the mean time, effort should be made to increase 
survival for one of the hitherto most fatal of all malignancies.
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